View Cancer Clinical Trials
Clinical Study to Assess Entry of Chemotherapeutic Agents into Brain Metastases in Women with Breast Cancer
- To determine the concentration of certain chemotherapeutic drugs in brain metastases from breast cancer
- Age ≥ 18
- Histologically or cytologically documented breast carcinoma with suspected or known parenchymal brain metastases for which surgical resection or biopsy is clinically indicated.
- Karnofsky performance status ≥ 50
- Life expectancy of ≥3 months
- Patients must have the following laboratory parameters:
- Absolute granulocyte count ≥ 1500/mm3
- Platelet count ≥ 100,000 /mm3
- Hemoglobin ≥ 10 gm/dl
- Creatinine ≤ 1.5 x normal
- Bilirubin (total) ≤ 1.5 x normal
- AST ≤ 3 x normal
- Off cytotoxic chemotherapy ≥ 3 weeks (6 weeks for nitrosoureas, mitomycin-C).
- Patients may continue hormone therapy and trastuzumab.
- The patient's treating oncologist must agree that the patient would derive clinical benefit from receiving at least one of the following agents: capecitabine, cyclophosphamide, doxorubicin, gemcitabine, lapatinib, paclitaxel, trastuzumab, or vinorelbine
- Off cranial radiation therapy ≥ 4 weeks
- Women of childbearing potential must have a negative urine or serum pregnancy test at screening.
- All patients of reproductive potential must agree to use an effective method of contraception during the study and three months following termination of treatment.
- Any toxicity > grade 2 felt to be from prior chemotherapy or radiation therapy at time of study entry.
- Patients who have received cytotoxic chemotherapy within 3 weeks (2 weeks for non-cytotoxic drugs [e.g., small molecule targeted drugs] and 6 weeks for nitrosoureas, mitomycin-C)
- Patients who have received bevacizumab in past 60 days
- Patients taking any experimental therapies
- Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease.
- Pregnant or lactating females
- A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2013 Cleveland Clinic. All rights reserved.